摘要
脓毒症是一种高发病率和高死亡率的危重症,继发血小板减少是导致患者死亡的独立危险因素,联合升血小板药物的替代治疗已成为该病的治疗趋势,血小板减少在脓毒症中的作用机制以及升血小板药物在脓毒症继发血小板减少中的临床疗效和安全性值得重视。本文综述脓毒症和血小板减少之间的关联以及脓毒症继发血小板减少的临床治疗现状,供进一步研究和临床治疗参考。
Sepsis is a disease with high morbidity and mortality in clinical,secondary thrombocytopenia syndrome is an independent risk factor for the mortality of sepsis,the use of platelet increased drug for replacement therapy becomes an inevitable trend.So we should pay more attention to the mechanism of thrombocytopenia in sepsis,and do further studies to explore the clinical efficacy and safety of platelet-increased drug therapy in sepsis patients with thrombocytopenia.This review describes the relationship between thrombocytopenia and sepsis,and their clinical therapeutic progress.
出处
《世界临床药物》
CAS
2016年第9期583-587,共5页
World Clinical Drug
基金
上海市卫计委面上项目基金(编号:20124214)
